Nature Communications (Jan 2021)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

  • Jing-Hui Tian,
  • Nita Patel,
  • Robert Haupt,
  • Haixia Zhou,
  • Stuart Weston,
  • Holly Hammond,
  • James Logue,
  • Alyse D. Portnoff,
  • James Norton,
  • Mimi Guebre-Xabier,
  • Bin Zhou,
  • Kelsey Jacobson,
  • Sonia Maciejewski,
  • Rafia Khatoon,
  • Malgorzata Wisniewska,
  • Will Moffitt,
  • Stefanie Kluepfel-Stahl,
  • Betty Ekechukwu,
  • James Papin,
  • Sarathi Boddapati,
  • C. Jason Wong,
  • Pedro A. Piedra,
  • Matthew B. Frieman,
  • Michael J. Massare,
  • Louis Fries,
  • Karin Lövgren Bengtsson,
  • Linda Stertman,
  • Larry Ellingsworth,
  • Gregory Glenn,
  • Gale Smith

DOI
https://doi.org/10.1038/s41467-020-20653-8
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 14

Abstract

Read online

Here, the authors characterize a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, and show immunogenicity in baboons and protection in mice with Matrix-M adjuvanted vaccine.